Literature DB >> 19883423

Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation.

R Schwartz-Albiez1, R C Monteiro, M Rodriguez, C J Binder, Y Shoenfeld.   

Abstract

Natural antibodies are produced by B lymphocytes in the absence of external antigen stimulation. With their ability to recognize self, altered self and foreign antigens, they comprise an important first-line defence against invading pathogens, but are also important for tissue homeostasis. By recognizing oligosaccharides expressed on tumour cells and modified cell surface structures accompanying necrosis, natural antibodies have an important anti-tumorigenic function. IVIg contains a wide spectrum of specificities presented in normal plasma including natural antibodies and has been shown to exert inhibitory effects on tumour cells through a subfraction of anti-vascular endothelial growth factor immunoglobulin (Ig)G antibodies with anti-angiogenic properties. IgA antibodies also have potent immunomodulatory properties, being able to both induce and suppress immune responses. IgA-mediated inhibitory function is able to inhibit several inflammatory diseases including asthma and glomerulonephritis. Autoantibodies of the IgM type, on the other hand, have shown promising results in the treatment of multiple sclerosis. These autoantibodies promote remyelination rather than modulating inflammation. Oxidation-specific epitopes, as found in atherosclerotic lesions and on apoptotic cells, comprise one important target of natural antibodies. By recognizing these epitopes, natural antibodies neutralize proinflammatory responses and mediate atheroprotection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19883423      PMCID: PMC2801031          DOI: 10.1111/j.1365-2249.2009.04026.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  44 in total

1.  Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis.

Authors:  D B McGavern; P D Murray; C Rivera-Quiñones; J D Schmelzer; P A Low; M Rodriguez
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

Review 2.  Humoral autoimmunity as a mediator of CNS repair.

Authors:  A J Bieber; A Warrington; L R Pease; M Rodriguez
Journal:  Trends Neurosci       Date:  2001-11       Impact factor: 13.837

3.  Shrinkage of melanoma metastases following high dose intravenous immunoglobulin treatment.

Authors:  Y Shoenfeld; Y Levy; P Fishman
Journal:  Isr Med Assoc J       Date:  2001-09       Impact factor: 0.892

Review 4.  Innate and acquired immunity in atherogenesis.

Authors:  Christoph J Binder; Mi-Kyung Chang; Peter X Shaw; Yury I Miller; Karsten Hartvigsen; Asheesh Dewan; Joseph L Witztum
Journal:  Nat Med       Date:  2002-11       Impact factor: 53.440

Review 5.  A blast from the past: clearance of apoptotic cells regulates immune responses.

Authors:  John Savill; Ian Dransfield; Chris Gregory; Chris Haslett
Journal:  Nat Rev Immunol       Date:  2002-12       Impact factor: 53.106

6.  Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages.

Authors:  Sarah Shapiro; Yehuda Shoenfeld; Boris Gilburd; Esther Sobel; Nitza Lahat
Journal:  Cancer       Date:  2002-11-01       Impact factor: 6.860

7.  Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis.

Authors:  A E Warrington; K Asakura; A J Bieber; B Ciric; V Van Keulen; S V Kaveri; R A Kyle; L R Pease; M Rodriguez
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 8.  Primary immunodeficiency disorders: antibody deficiency.

Authors:  Mark Ballow
Journal:  J Allergy Clin Immunol       Date:  2002-04       Impact factor: 10.793

9.  Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity.

Authors:  P X Shaw; S Hörkkö; M K Chang; L K Curtiss; W Palinski; G J Silverman; J L Witztum
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

10.  Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans.

Authors:  Meng-Yun Chou; Linda Fogelstrand; Karsten Hartvigsen; Lotte F Hansen; Douglas Woelkers; Peter X Shaw; Jeomil Choi; Thomas Perkmann; Fredrik Bäckhed; Yury I Miller; Sohvi Hörkkö; Maripat Corr; Joseph L Witztum; Christoph J Binder
Journal:  J Clin Invest       Date:  2009-04-13       Impact factor: 14.808

View more
  38 in total

1.  Study of natural IgG antibodies against vascular endothelial growth factor receptor 1 in hepatocellular carcinoma.

Authors:  Yilai Wang; Zhaoping Yan; Yile Huang; Cailing Qiu; Xiangyun Chen; Ying Hu; Qingyong Meng; Jun Wei
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

Review 2.  A potential role of probiotics in colorectal cancer prevention: review of possible mechanisms of action.

Authors:  Esther Swee Lan Chong
Journal:  World J Microbiol Biotechnol       Date:  2013-09-26       Impact factor: 3.312

3.  Antibody repertoire profiling with mimotope arrays.

Authors:  Shina Pashova; Christoph Schneider; Stephan von Gunten; Anastas Pashov
Journal:  Hum Vaccin Immunother       Date:  2016-12-08       Impact factor: 3.452

4.  Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases.

Authors:  Gisele Zandman-Goddard; Alexander Krauthammer; Yair Levy; Pnina Langevitz; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

Review 5.  A Special Connection between γδ T Cells and Natural Antibodies?

Authors:  Willi K Born; Yafei Huang; Wanjiang Zeng; Raul M Torres; Rebecca L O'Brien
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-05-27       Impact factor: 4.291

6.  Presence of preexisting antibodies mediates survival in sepsis.

Authors:  Rituparna Moitra; Dominic R Beal; Bryan G Belikoff; Daniel G Remick
Journal:  Shock       Date:  2012-01       Impact factor: 3.454

7.  Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies.

Authors:  Oliver M T Pearce; Heinz Läubli; Andrea Verhagen; Patrick Secrest; Jiquan Zhang; Nissi M Varki; Paul R Crocker; Jack D Bui; Ajit Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-07       Impact factor: 11.205

8.  Influence of the serum levels of immunoglobulins on clinical outcomes in medical intensive-care patients.

Authors:  C Geier; J Schröder; A Tamm; S Dietz; S Nuding; K Holder; Ö Khandanpour; K Werdan; H Ebelt
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-12-17       Impact factor: 0.840

9.  The novel panel assay to define tumor-associated antigen-binding antibodies in patients with metastatic melanomas may have diagnostic value.

Authors:  Beatrix Kotlan; Gabriella Liszkay; Miri Blank; Orsolya Csuka; Timea Balatoni; Laszlo Toth; Klara Eles; Szabolcs Horvath; Gyorgy Naszados; Judit Olasz; Balazs Banky; Jozsef Toth; Maria Godeny; Francesco M Marincola; Miklos Kasler; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

Review 10.  The advantage of specific intravenous immunoglobulin (sIVIG) on regular IVIG: experience of the last decade.

Authors:  Nina Svetlicky; Oscar-Danilo Ortega-Hernandez; Luc Mouthon; Loic Guillevin; Hans-Jurgen Thiesen; Arie Altman; Martine Szyper Kravitz; Miri Blank; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2012-12-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.